Clinical Trial Update: AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the addition of plerixafor (AMD3100) to a G-CSF mobilization regimen to increase peripheral blood stem cells in patients with Hodgkin l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Mozobil (Plerixafor) (Plerixafor)
• Neupogen (filgrastim) (filgrastim)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Hodgkin's Disease | Phase 2 | Status: COMPLETED | Results posted: 2010-10-06